Medicamen Biotech reported a significant improvement in profitability for the first quarter of FY27, with standalone net profit rising 54% year-on-year to ₹252.69 lakh. Consolidated net profit attributable to controlling interest grew 14% YoY to ₹211.84 lakh. The financial performance was underpinned by top-line growth, as standalone revenue from operations increased 14% to ₹4,385.27 lakh, while consolidated revenue rose 11% to ₹4,789.69 lakh.

The company’s operational efficiency improved alongside revenue growth. Standalone profit before tax (PBT) expanded 50% YoY to ₹325.79 lakh, driven by higher income from operations outpacing the increase in material and employee costs. Consolidated PBT also saw a robust 21% YoY increase to ₹257.17 lakh.

Financial Performance Highlights

The following table outlines the key financial metrics for the quarter ended June 30, 2026, compared to the same period last year:

What the Numbers Show

A notable divergence exists between the standalone and consolidated profit growth rates. While standalone net profit surged 54%, consolidated net profit attributable to equity shareholders grew by only 14%. This suggests that the subsidiaries, Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited, contributed less proportionally to the bottom-line expansion compared to the parent entity. Additionally, other income declined significantly on a standalone basis, falling to ₹86.16 lakh from ₹172.63 lakh in the previous quarter, indicating that the core operational revenue growth was the primary driver of the quarter's success rather than ancillary gains.

Board Approvals and Corporate Actions

During its meeting held on August 14, 2026, the Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026. The board also approved the draft Annual Report and Cost Audit Report for FY26.

Key corporate actions include:

• Dividend Recommendation: The board recommended a final dividend of 10%, i.e., Re 1 per equity share, subject to shareholder approval at the Annual General Meeting (AGM).
• AGM Schedule: The 33rd AGM is scheduled for September 26, 2026, via video conferencing. The record date for determining voting eligibility is September 19, 2026.
• Register Closure: The register of members will remain closed from September 19 to September 25, 2026, in connection with the dividend payment.

Regulatory Compliance

The board took note of communications from BSE Limited and NSE regarding non-compliance with Regulation 19(1)/19(2) of the SEBI (LODR) Regulations, 2015, concerning the constitution of the Nomination and Remuneration Committee. Fines totaling ₹1,10,920 each (including GST) were levied by both exchanges. The company confirmed that these payments were made on June 2, 2026, and directed management to ensure strict adherence to future compliance requirements.

Promoter Shivalik Rasayan Limited has disclosed its shareholding in Medicamen Biotech Limited for the year ended March 31, 2026. The filing confirms that the promoter continues to hold a significant stake in the pharmaceutical company without creating any encumbrances on the shares during the financial year.

Shareholding Details

As per the disclosure submitted under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Shivalik Rasayan Limited holds 54,87,095 equity shares. This stake translates to 40.46% of the total equity share capital of Medicamen Biotech Limited as of March 31, 2026.

Encumbrance Status

The promoter explicitly stated that no encumbrance was created, directly or indirectly, on the held shares during the Financial Year 2025-26. This declaration provides clarity regarding the leverage-free status of the promoter's holding for the specified period.

The disclosure was filed by Rahul Bishnoi, Director of Shivalik Rasayan Limited, and submitted to the stock exchanges on April 7, 2026. Parul Choudhary, Company Secretary & Compliance Officer of Medicamen Biotech Limited, forwarded the disclosure to the exchanges.